engleski

Use of Recombinant Factor VIIa (NovoSeven) in the management od postoperative bleeding in thoracic surgery patients

Background: Thoracic surgery belongs to the group of "major surgery" where patients are frequently threatened for massive postoperative haemorrhage, which is closely related to prolonged postoperative morbidity and early patient mortality (23%). Recombinant factor VIIa induces haemostasis at the site of injury independent of the presence of FVIII and FIX by forming complexes with exposed tissue factor. Case description: We present favorable result obtained by use of rFVII in four patients in whom the life-threatening haemorrhage following the procedure of lung resection was successfully stopped. The early use of this agent in our patients contributed considerably to the maintenance of their satisfactory clinical and laboratory status and certainly prevented prolonged morbidity and possible fatal outcome of the operative treatment. Conclusion: We would like to contribute our modest clinical experience in the use of rFVII suggests it to be a safe and efficacious agent to institute and maintain hemostasis after life-threatening postoperative bleeding in thoracic surgery.

thoracic surgery; intensive care; haemorrhage; coagulation; recombinant factor (NovoSeven)

nije evidentirano